This document provides an agenda for a presentation on Janssen (a division of Johnson & Johnson). The agenda includes an introduction to J&J, Janssen's organizational structure and divisional model, their vision, mission, strategy and goals, sustainability approach, an example product (Balversa), work culture, SWOT analysis, and financial statements and ratios. Key points covered are Janssen's focus on access to affordable medicines, developing innovative products, and their Earthwards sustainability program.

1. Contemporary Management
Final Project
Janssen (a J&J company)

2. AGENDA
 Company Introduction
 Org Structure
 Vision, Mission, Strategy & Goals
 Sustainability & Earthwards approach
 Balversa ®
 Work Culture
 SWOT Analysis
 Financial Statements & Ratios.

3. A little Introduction…
Johnson & Johnson (J&J) is a leading diversified multinational
company founded in 1886.
J&J has three business sectors

4. Janssen Facts

5. Janssen Org Structure
Org structure of Janssen Company is
the divisional structure is a type of
organizational structure that groups
each organizational function into a
division, Each division contains all the
necessary resources and functions
within it to support that product line or
geography

6. Janssen Org Structure

7. Janssen Org Structure

8. Janssen Competitive Position

9. Cilag Layout & Manufacturing Process

10. Vision: strive to provide access to effective and affordable
medicines and related health care services to the people who need
them.
Mission: make the most fundamental change in the way diseases
are managed.
Goals: We are building great healthcare solutions that will bring
benefits to patients and add value to society and our company’s
stakeholders.
Developing innovative and integrated products and
medicines to restore and extend the quality of life.
Strategy: Horizontal integration, growth strategy
Developing procurement relationships based on trust.
Vision & missiom

11. Sustainability is managing our personal, business and
societal impacts to ensure better outcomes for patients and
society.
 Committed to Clean, Renewable Energy.
 Reduced 20% in CO2 emissions by 2020.
 Reduced waste volumes by 10% compared to 2010.
 Reduced water consumption by 10% compared to 2010.
 Product Stewardship Through the Lifecycle: Green
Chemistry and Technology Yield Business and
Environmental Benefits.
Janssen Environmental Sustainability Strategy:

12. The Unique Johnson & Johnson Program That's Helping to
Create a More Sustainable World
Defines how Johnson & Johnson addresses the
environmental and social impacts of their products, and
engages development teams in designing innovative and
more sustainable solutions across a product’s lifecycle,
from formulation and manufacturing, to product use and
end-of-life.
The Earthwards® approach

13. Surgicel® Absorbable Hemostat
a fabric designed to absorb bleeding during
surgery, discovered that folding the mesh instead
of rolling it saved a whole lot of space during
packing.
The Earthwards® approach

14. Stelara®
At one time, users of Stelara, which treats plaque psoriasis
and psoriatic arthritis, received six injections per year. The
medication’s new formula has streamlined that number down
to four injections per year—leading to a 92% reduction in
primary packaging, as well as 90% less material being
consumed per patient.
The Janssen biopharmaceutical plants that manufacture the
drug also get 50% of their power from such renewable
sources as solar and wind energy.
The Earthwards® approach

15. BALVERSA® (erdafitinib)
A prescription medicine used to treat adults with bladder
cancer (urothelial cancer) that has spread or cannot be
removed by surgery.
Researchers have investigated erdafitinib for safety and
efficacy in treatment of bile duct cancer, gastric cancer, non-
small cell lung cancer, and esophageal cancer.
In April 2019, erdafitinib was granted approval by the FDA
for treatment of metastatic or locally advanced bladder
cancer with an FGFR3 or FGFR2 alteration.
Example for Janssen Products:

16. Johnson & Johnson Organization Culture
“A Family Company at Work for a
Better World”
1- Inclusive environment, Sense of
Security & Compensation.
2- Organization Credo, Suggestions &
complains.
3- Socialization, Work Life balance.
4- Formal Events
5- Enhancement

17. work culture (According to their career center)
 Committed to Caring
 Responsible to our communities
 Ready to apply our knowledge and
know-how
 Unique in our background and
experiences
 The drivers of our own success
 Passionate about doing what’s right

18. More than half of the first 14 employees at Johnson
& Johnson were women, and we continue to believe
that a diverse and inclusive workplace—one where
everyone feels they belong—is not only a business
imperative but a key driver of our growth today.
The world is changing—fast. But we know that by
aligning with and serving the needs of our diverse
and multicultural stakeholders, from patients to
employees, consumers and customers, we can
unlock tremendous potential for growth.
Diversity

19. Credo Based Company (5 star rating)
The company is a credo based company and try to live by
it.
Politics, compliance and red tape galore (2 star rating)
it’s not about being the best candidate but being the
person who falls in line easiest. If you have an opinion
and are an outspoken individual, you’ll get shunned for it.
Reviews on Janssen work culture from Indeed.com

20. STRENGTHS
 Worldwide: affiliate of Johnson and Johnson
 Most versatile producer of medical products in the
world
 Good reputation, profitable and innovative company
 Strong R&D commitment and productivity
 Stable market share and performance
 High product quality
 Brightest employees and researchers
 Leader in medications for Cancer
WEAKNESSES
 Expensive products
 Research takes several years (long time)
 Long training years for employees and
researchers
 Uses rare and dangerous substances
(chemotherapy)
 Any manufacturing defect: global consequences.
 Any mistake= whole process lost= extra cost
Opportunities
 COVID-19 = Johnson and Johnson vaccine
 New diseases = new medications
 Consistent customer growth
 Sustainability
Threats
 Increasing competition
 Complex chemistry procedures
 Any small problem consider worldwide problem
 Expensive sector ( high cost)
SWOT Analysis

21. SWOT Analysis
STRENGTHS
 Worldwide: affiliate of Johnson and Johnson
 Most versatile producer of medical products in the world
 Good reputation, profitable and innovative company
 Strong R&D commitment and productivity
 Stable market share and performance
 High product quality
 Brightest employees and researchers
 Leader in medications for Cancer

22. SWOT Analysis
WEAKNESSES
 Expensive products
 Research takes several years (long time)
 Long training years for employees and researchers
 Uses rare and dangerous substances (chemotherapy)
 Any manufacturing defect: global consequences.
 Any mistake= whole process lost= extra cost

23. SWOT Analysis
Opportunities
 COVID-19 = Johnson and Johnson vaccine
 New diseases = new medications
 Consistent customer growth
 Sustainability

24. SWOT Analysis
Threats
 Increasing competition
 Complex chemistry procedures
 Any small problem consider worldwide problem
 Expensive sector ( high cost)

25. Operating Budgets
Segment Square Feet (in thousands)
Consumer Health 4,684
Pharmaceutical 5,559
Medical Devices 4,951
Worldwide Total 15,194

26. The financial statements

27. The financial statements

28. Earnings before taxes

29. Rebates

30. Pricing

31. Cost of Products Sold
The intangible asset amortization
expense included in cost of products
sold was $4.7 billion (2020) and $4.5
billion (2019)

32. Ratios In 2020
A. Liquidity Ratios : Current Ratio (Current Assets / Current
Liabilities) = 51237 / 42493 = 1.206
B. Debt Management Ratios: Debt Ratio = Total Debt / Total
Assets = 111,616 / 174,894 = 0.64
C. Assets utilization / management i.e. Activity Ratios: Total
Assets Turnover = Sales / Total Assets = 82,584 / 174,894 =
0.47
D. Profitability Ratios :
1- Sales: Net Income Margin (NIM) (Net Income / Sales) =
14,714 / 82,584 =0.178
2- Financial Performances: Return on Equity (ROE)= Earning
before Tax / Equity= 16,497 / 63,278 = 0.26

33. •Prepared by: Group 1A
•Marina Adel
•Esraa Magdy
•Dalia Sobhi
•Norhan Salah
•Yasmin Farouk